Cefoxitin: An alternative to carbapenems in urinary tract infections due to extended-spectrum beta-lactamase-producing Enterobacteriaceae.

Abstract

BACKGROUND AND OBJECTIVES:

Infections caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBL-E) have become a major public health issue worldwide. Cefoxitin is a second-generation cephalosporin and is associated with a strong in vitro activity against ESBL.

PATIENTS AND METHODS:

We conducted a prospective monocentric cohort study from 2012 to 2015 to evaluate the clinical efficacy and safety of cefoxitin in 15 patients treated for urinary tract infection (UTI) caused by ESBL-E, without any severity criteria.

RESULTS:

We included 15 patients; 11 were male patients with defined risk factors for ESBL-E. Ten patients presented with male UTI, three with pyelonephritis, and two with cystitis. Escherichia coli was the predominant pathogen. All patients had a positive outcome with a good tolerance (a skin rash without any sign of severity was observed in one patient). Microbiological cure was obtained in 9 patients out of 10 at the end of treatment.

CONCLUSION:

Cefoxitin is an alternative treatment to carbapenems for urinary tract infections caused by ESBL-producing Enterobacteriaceae.

• Authors: A Mambie, F Vuotto, D Poitrenaud, P Weyrich, O Cannesson, R Dessein, K Faure, B Guery, T Galpérine
• Journal: Medecine et maladies infectieuses (Med Mal Infect) Vol. 46 Issue 4 Pg. 215-9 (Jun 2016) ISSN: 1769-6690 [Electronic] France
• PMID: 27210283 (Publication Type: Journal Article, Observational Study)
• Copyright: Copyright © 2016 Elsevier Masson SAS. All rights reserved.

Chemical References

• Anti-Bacterial Agents
• Bacterial Proteins
• Cefoxitin
• beta-Lactamases

Topics

• Anti-Bacterial Agents (adverse effects, therapeutic use)
• Bacterial Proteins (metabolism)
• Cefoxitin (adverse effects, therapeutic use)
• Drug Eruptions (etiology)
• Escherichia coli Infections (drug therapy)
• Female
• Humans
• Klebsiella Infections (drug therapy)
• Klebsiella pneumoniae (drug effects, enzymology)
• Male
• Middle Aged
• Prospective Studies
• Treatment Outcome
• Urinary Tract Infections (drug therapy)
• Uropathogenic Escherichia coli (drug effects, enzymology)
• beta-Lactam Resistance
• beta-Lactamases (metabolism)